In this segment of the Motley Fool's Market Check-Up, Fool health-care analyst David Williamson takes investors through some of the biggest stories affecting Big Pharma, biotech stocks, and the health insurance industry today.

Pfizer (NYSE:PFE) has come to terms with generic drugmaker Teva Pharmaceuticals (NYSE:TEVA) over its erectile dysfunction drug Viagra, with Teva due to launch its generic version two years early in 2017. As this will be earlier than Pfizer's patent expiration on the drug, Teva will be paying Pfizer an undisclosed royalty on sales, which should mitigate some of the damage the generic competitor would do. In this video, David tells investors why he thinks this is a great deal for Teva going forward, and talks about the most important catalyst for Pfizer investors on the horizon today.

David Williamson owns shares of Pfizer. The Motley Fool recommends Teva Pharmaceutical Industries. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.